Eribulin and Lenvatinib in Advanced Solid Tumors

Exclusion Criteria

• •Lesions that have been radiated previously cannot be considered target lesions
• •Prior treatment related side effects must have resolved to \< Grade 2 severity per Common Terminology Criteria for Adverse Events (CTCAE version 4.03), except alopecia and infertility.
• •1. GI tract disease resulting in an inability to take oral medication
• •2. Malabsorption syndrome
• •3. Require IV alimentation
• •4. History of prior surgical procedures affecting absorption
• •5. Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).
• •6. Hypersensitivity of any of the components of eribulin or lenvatinib
• •7. History of significant neurological ( no neuropathy more than grade 2) or psychiatric disorders
• •8. Significant non neoplastic liver disease (Cirrhosis, active chronic hepatitis)
• •9. Immunocompromised subjects, including patients with human immunodeficiency virus
• •10. Significant non neoplastic renal disease
• •11. Active infection requiring systemic therapy.
• •12. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment
• •13. Prolongation of QTc interval to more than 480 milliseconds when electrolyte balance is normal
• •14. Major surgery within 4 weeks prior to first dose of the study drug.